A 2-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo Versus Carboplatin, Pemetrexed Plus Truncated Demcizumab as First-Line Treatment in Subjects With Stage IV Non-Squamous Non-Small Cell Lung Cancer

Trial Profile

A 2-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo Versus Carboplatin, Pemetrexed Plus Truncated Demcizumab as First-Line Treatment in Subjects With Stage IV Non-Squamous Non-Small Cell Lung Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2017

At a glance

  • Drugs Demcizumab (Primary) ; Carboplatin; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms DENALI
  • Sponsors OncoMed Pharmaceuticals
  • Most Recent Events

    • 25 Sep 2017 This study has been completed in Belgium.
    • 23 Jul 2017 This study has been completed in Spain (End date:2017-07-04)
    • 08 May 2017 Status changed from active, no longer recruiting to discontinued, according to an OncoMed Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top